News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


No Impact With Mifepristone in Patients With Meningioma


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

 This is a small study, but the patients in the placebo group did better than those who took Mifepristone for meningiomas.



Website: http://www.cancertherapyadvisor.com/brain-cancer/meningioma-brain-cancer-mifepristone-no-treatment-benefit/article/451334/

Posted on: 11/04/2015

Stephen Cho
November 03, 2015
No Impact With Mifepristone in Patients With Meningioma
 
Share this article:
facebook
twitter
linkedin
google
Comments
Email
Print
Long-term administration of mifepristone is well-tolerated in patients with unresectable meningioma, but has no impact in terms of survival.
Long-term administration of mifepristone is well-tolerated in patients with unresectable meningioma, but has no impact in terms of survival.
Long-term administration of mifepristone is well-tolerated in patients with unresectable meningioma, but has no impact in terms of failure-free or overall survival, according to a study published online ahead of print in the Journal of Clinical Oncology.1
 
In a multicenter, prospective, randomized, placebo-controlled phase 3 trial, researchers led by Yongli Ji, MD, of the University of Vermont Cancer Center in Burlington, VT, randomly assigned 164 patients to either mifepristone or placebo for 2 years or until disease progression.
 
Patients who were stable or had responded to therapy after 2 years had the option to continue therapy, and time to treatment failure and overall survival rate were measured.
 
 
RELATED: Proton Therapy Well-Tolerated for Low-Grade Gliomas
 
The researchers found that 24 patients were able to complete 2 years of mifepristone without disease progression, adverse effects, or other reasons for discontinuation. In addition, 28 patients in the placebo group were able to complete the 2-year study.
 
They observed no statistical difference between the 2 arms in terms of failure-free or overall survival, and concluded that long-term administration of mifepristone had no significant impact on this patient population.
 
Reference
 
Ji Y, Rankin C, Grunberg S, et al. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005 [published online ahead of print November 2, 2015]. J Clin Oncol. doi: 10.1200/JCO.2015.61.6490.

 




Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740